Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer.
Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G. Sacconi A, et al. Among authors: mottolese m. Cell Death Dis. 2012 Nov 15;3(11):e423. doi: 10.1038/cddis.2012.160. Cell Death Dis. 2012. PMID: 23152059 Free PMC article.
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours.
Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E, Blandino G. Biagioni F, et al. Among authors: mottolese m. EMBO Mol Med. 2012 Nov;4(11):1214-29. doi: 10.1002/emmm.201201483. EMBO Mol Med. 2012. PMID: 23125021 Free PMC article.
Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells.
Folgiero V, Di Carlo SE, Bon G, Spugnini EP, Di Benedetto A, Germoni S, Pia Gentileschi M, Accardo A, Milella M, Morelli G, Bossi G, Mottolese M, Falcioni R. Folgiero V, et al. Among authors: mottolese m. Cell Death Dis. 2012 Dec 6;3(12):e440. doi: 10.1038/cddis.2012.179. Cell Death Dis. 2012. PMID: 23222510 Free PMC article.
miR-155 drives telomere fragility in human breast cancer by targeting TRF1.
Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, Benetti R, Mottolese M, Schneider C, Blandino G, Schoeftner S. Dinami R, et al. Among authors: mottolese m. Cancer Res. 2014 Aug 1;74(15):4145-56. doi: 10.1158/0008-5472.CAN-13-2038. Epub 2014 May 29. Cancer Res. 2014. PMID: 24876105
Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres.
Melucci E, Cosimelli M, Carpanese L, Pizzi G, Izzo F, Fiore F, Golfieri R, Giampalma E, Sperduti I, Ercolani C, Sciuto R, Mancini R, Garufi C, Diodoro MG, Mottolese M; Italian Society of Locoregional Therapies in Oncology (S.I.T.I.L.O.). Melucci E, et al. Among authors: mottolese m. J Exp Clin Cancer Res. 2013 Mar 6;32(1):13. doi: 10.1186/1756-9966-32-13. J Exp Clin Cancer Res. 2013. PMID: 23497522 Free PMC article. Clinical Trial.
Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.
Ercolani C, Di Benedetto A, Terrenato I, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Buglioni S, Ramieri MT, Mentuccia L, Gamucci T, Perracchio L, Pescarmona E, Mottolese M, Barba M, Vici P, De Maria R, Maugeri-Saccà M. Ercolani C, et al. Among authors: mottolese m. Cancer Biol Ther. 2017 May 4;18(5):339-346. doi: 10.1080/15384047.2017.1312230. Epub 2017 Apr 7. Cancer Biol Ther. 2017. PMID: 28387539 Free PMC article.
243 results